临床前和1期临床试验结果表明:UBX1325可能有助于DME治疗更有效、持久。近日,研究成果以Therapeutic targeting of cellular senescence in diabetic macular edema:preclinical and phase 1 trial results为题发表于Nature Medicine期刊。 研究...
UNITY 预计将在年底之前分享来自另一组湿性 AMD 患者的 8 周数据,以及来自 1 期单次递增剂量研究的原始队列的完整 24 周数据。 https://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-announces-positive-12-week-data-phase-1...
我们期待在最近启动的 2a 期研究中进一步探索这种新机制在改变 DME 患者疾病进展过程中的功效。” https://www.globenewswire.com/news-release/2021/07/06/2258086/0/en/UNITY-Biotechnology-Announces-Positive-Data-from-Phase-1-Clinical-Trial-of-UBX1325-in-Patients-with-Advanced-Vascular-Eye-Disease.html...
1.UNITY Biotechnology announces positive data from Phase I clinical trial of UNX1325 in patients with advanced vascular eye disease. Link: 2.https://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-...
Unity Biotechnology公司官方新闻稿件:https://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-announces-positive-data-phase-2-behold-study 关于亚盛医药(6855.HK) 亚盛医药是一家立足中国、面向全球的生物医药企业,致力于在肿瘤、乙肝及与衰老相关的疾病等治疗领域开发创新药物。2019...
1.UNITYBiotechnology announces positive data from Phase I clinical trial of UNX1325 inpatients with advanced vascular eye disease. Link:https://ir.unitybiotechnology.com/news-releases/news-release-details/unity-biotechnology-announc...